Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/SN/A
P/E—
Fwd P/E13.65
PEG1.66
52W— – —
RSI—
Target$98.44 (+12.5%)
Beta0.58
Div3.27%
Loading chart…
RSI (14)
Loading patterns…
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 66
Overbought · 100
Signal
Neutral
EMA Price Levels
Volume Analysis
Momentum Dashboard
Trend Strength
Detected Patterns
4Bullish
2Bearish
0Neutral
▲ Double Bottom — Two lows ~$73.19 — bullish reversal confirmed
▲ Double Bottom — Two lows ~$77.53 — bullish reversal confirmed
▲ Bull Flag — Breakout after +9% pole — bullish continuation
▲ Double Bottom — Two lows ~$78.56 — bullish reversal confirmed
▼ Bear Flag — Breakdown after -10% pole — bearish continuation
▼ Bear Flag — Breakdown after -12% pole — bearish continuation
View overlays on the price chart via Chart tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$98.44
+12.5% upside
Low $78
—
High $121
Consensus
Current price
Wall Street Analyst Ratings
| Firm | Rating | Change | Action | Date |
|---|---|---|---|---|
| UBS | Buy | Neutral → Buy | ▲ Upgrade | 2026-07-28 |
| TD Cowen | Buy | — | ↔ Maintain | 2026-07-10 |
| Evercore ISI Group | Outperform | — | ↔ Maintain | 2026-07-06 |
| Needham | Buy | — | ↔ Reiterate | 2026-06-17 |
| Goldman Sachs | Neutral | — | ↔ Maintain | 2026-06-05 |
| Bernstein | Outperform | — | ↔ Maintain | 2026-06-05 |
| RBC Capital | Outperform | — | ↔ Reiterate | 2026-06-04 |
| Wells Fargo | Overweight | — | ↔ Maintain | 2026-06-04 |
| Leerink Partners | Outperform | — | ↔ Maintain | 2026-06-04 |
| Baird | Neutral | — | ↔ Maintain | 2026-06-04 |
| BTIG | Buy | Neutral → Buy | ▲ Upgrade | 2026-06-04 |
| Mizuho | Outperform | — | ↔ Maintain | 2026-06-03 |
| Truist Securities | Hold | — | ↔ Maintain | 2026-04-15 |
| Citigroup | Buy | — | ↔ Maintain | 2026-04-07 |
| Argus Research | Buy | — | ↔ Maintain | 2026-04-06 |
| Barclays | Overweight | — | ↔ Maintain | 2026-04-01 |
| Piper Sandler | Neutral | — | ↔ Maintain | 2026-04-01 |
| JP Morgan | Neutral | — | ↔ Maintain | 2026-02-18 |
| William Blair | Outperform | Market Perform → Outperform | ▲ Upgrade | 2026-01-06 |
| Morgan Stanley | Overweight | — | ↔ Maintain | 2025-11-19 |
UBS
2026-07-28
Buy
(from Neutral)
▲ Upgrade
TD Cowen
2026-07-10
Buy
↔ Maintain
Evercore ISI Group
2026-07-06
Outperform
↔ Maintain
Needham
2026-06-17
Buy
↔ Reiterate
Goldman Sachs
2026-06-05
Neutral
↔ Maintain
Bernstein
2026-06-05
Outperform
↔ Maintain
RBC Capital
2026-06-04
Outperform
↔ Reiterate
Wells Fargo
2026-06-04
Overweight
↔ Maintain
Leerink Partners
2026-06-04
Outperform
↔ Maintain
Baird
2026-06-04
Neutral
↔ Maintain
BTIG
2026-06-04
Buy
(from Neutral)
▲ Upgrade
Mizuho
2026-06-03
Outperform
↔ Maintain
Truist Securities
2026-04-15
Hold
↔ Maintain
Citigroup
2026-04-07
Buy
↔ Maintain
Argus Research
2026-04-06
Buy
↔ Maintain
Barclays
2026-04-01
Overweight
↔ Maintain
Piper Sandler
2026-04-01
Neutral
↔ Maintain
JP Morgan
2026-02-18
Neutral
↔ Maintain
William Blair
2026-01-06
Outperform
(from Market Perform)
▲ Upgrade
Morgan Stanley
2025-11-19
Overweight
↔ Maintain
Profitability
Gross Margin
65.31%TTM
Op. Margin
22.05%TTM
ROE
9.84%TTM
Rev. Growth
9.90%YoY
Free Cash Flow
4.63BTTM
FCF Yield
—TTM
Balance Sheet
Debt / Equity
58.21MRQ
Current Ratio
2.13MRQ
Cash
9.22BMRQ
Total Debt
29.15BMRQ
Net Debt
—MRQ
Income
Div. Yield
3.27%TTM
Annual Rate
2.88Fwd
Payout Ratio
76.14%TTM
Dividend History
Payout Ratio (TTM): 76.14%
| Date | Amount / Share | Yield at Payment |
|---|---|---|
| 2026-06-26 | $0.7200 | 0.89% |
| 2026-03-27 | $0.7100 | 0.82% |
| 2025-12-26 | $0.7100 | 0.75% |
| 2025-09-26 | $0.7100 | 0.77% |
| 2025-06-27 | $0.7100 | 0.85% |
| 2025-03-28 | $0.7000 | 0.83% |
| 2024-12-27 | $0.7000 | 0.91% |
| 2024-09-27 | $0.7000 | 0.83% |
| 2024-06-28 | $0.7000 | 0.95% |
| 2024-03-21 | $0.6900 | 0.89% |
| 2023-12-19 | $0.6900 | 0.91% |
| 2023-09-21 | $0.6900 | 0.94% |
| 2023-06-22 | $0.6900 | 0.87% |
| 2023-03-23 | $0.6800 | 0.97% |
| 2022-12-20 | $0.6800 | 0.99% |
| 2022-09-22 | $0.6800 | 0.92% |
| 2022-06-23 | $0.6800 | 0.88% |
| 2022-03-24 | $0.6300 | 0.68% |
| 2021-12-21 | $0.6300 | 0.72% |
| 2021-09-23 | $0.6300 | 0.56% |
| 2021-06-24 | $0.6300 | 0.59% |
| 2021-03-25 | $0.5800 | 0.58% |
| 2020-12-21 | $0.5800 | 0.60% |
| 2020-09-24 | $0.5800 | 0.68% |
| 2020-06-25 | $0.5800 | 0.78% |
| 2020-03-26 | $0.5400 | 0.71% |
| 2019-12-26 | $0.5400 | 0.58% |
| 2019-09-26 | $0.5400 | 0.61% |
| 2019-07-05 | $0.5400 | 0.67% |
| 2019-03-21 | $0.5000 | 0.67% |
| 2018-12-27 | $0.5000 | 0.69% |
| 2018-07-05 | $0.5000 | 0.72% |
| 2018-03-22 | $0.4600 | 0.73% |
| 2017-12-28 | $0.4600 | 0.71% |
| 2017-09-28 | $0.4600 | 0.75% |
| 2017-07-05 | $0.4600 | 0.66% |
| 2017-03-22 | $0.4300 | 0.68% |
| 2016-12-21 | $0.4300 | 0.77% |
| 2016-09-27 | $0.4300 | 0.64% |
| 2016-07-06 | $0.4300 | 0.64% |
How MDT Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | N/A |
| Enterprise Value | 132.59B |
| Trailing P/E | 23.28 |
| Forward P/E | 13.65 |
| PEG Ratio (5yr) | 1.66 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.27 |
| EV/Revenue | 3.65 |
| EV/EBITDA | 13.12 |
Share Statistics
| Avg Vol (3m) | 10.04M |
| Shares Outstanding | N/A |
| Float | 1.28B |
| % Held by Insiders | 0.31% |
| % Held by Institutions | 89.34% |
| Short Ratio | 2.05 |
| Short % of Float | 1.49% |
Profitability
| Gross Margin | 65.31% |
| Operating Margin (ttm) | 22.05% |
| Profit Margin | 13.20% |
| Return on Assets (ttm) | 4.92% |
| Return on Equity (ttm) | 9.84% |
Income Statement
| Revenue (ttm) | 36.36B |
| Revenue Growth (yoy) | 9.90% |
| Gross Profit (ttm) | 23.75B |
| EBITDA | 10.10B |
| Net Income (ttm) | 4.80B |
| Diluted EPS (ttm) | 3.76 |
| EPS Growth (yoy) | 18.30% |
Balance Sheet
| Total Cash (mrq) | 9.22B |
| Total Debt (mrq) | 29.15B |
| Debt / Equity (mrq) | 58.21 |
| Current Ratio (mrq) | 2.13 |
| Book Value / Share | 38.64 |
| Operating CF (ttm) | 7.33B |
| Free Cash Flow (ttm) | 4.63B |
Trading & Dividends
| Beta (5Y) | 0.58 |
| 50-Day MA | 80.51 |
| 200-Day MA | 90.21 |
| Fwd Dividend Yield | 331.00% |
| Payout Ratio | 76.14% |
Ownership Breakdown
Institutional 89.34%
Insider 0.31%
Public 10.3%
Short Interest
1.49% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in MDT in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-08 | WALTER MATTHEW R. | Officer | Sale at price 83.15 per share. | 3,102 | $257,931 |
| 2026-06-08 | KIIL HARRY SKIP | Officer | Sale at price 80.44 - 80.45 per share. | 4,189 | $336,965 |
| 2026-05-26 | MARINARO MICHAEL | Officer | 18,994 | — | |
| 2026-05-26 | WALTER MATTHEW R. | Officer | 9,149 | — | |
| 2026-05-26 | BLOMQUIST DENISE L | Officer | 1,712 | — | |
| 2026-05-26 | KIIL HARRY SKIP | Officer | 15,195 | — | |
| 2026-05-26 | WALL BRETT A | Officer | 26,907 | — | |
| 2026-05-26 | MARTHA GEOFFREY S | Chief Executive Officer | 94,963 | — | |
| 2026-04-27 | BLOMQUIST DENISE L | Officer | Stock Award(Grant) at price 0.00 per share. | 1,508 | — |
| 2026-04-27 | LEE JOON SUP | Director | Stock Award(Grant) at price 0.00 per share. | 1,803 | — |
| 2026-04-27 | NABEL ELIZABETH G | Director | Stock Award(Grant) at price 0.00 per share. | 2,111 | — |
| 2026-04-27 | GROETELAARS JOHN P | Director | Stock Award(Grant) at price 0.00 per share. | 1,444 | — |
| 2026-04-27 | LEWIS GREGORY P | Director | Stock Award(Grant) at price 0.00 per share. | 2,111 | — |
| 2026-04-27 | JELLISON WILLIAM R | Director | Stock Award(Grant) at price 0.00 per share. | 1,444 | — |
| 2026-04-27 | POWELL KENDALL J | Director | Stock Award(Grant) at price 0.00 per share. | 2,111 | — |
| 2026-04-27 | DONNELLY SCOTT C | Director | Stock Award(Grant) at price 0.00 per share. | 2,111 | — |
| 2026-04-27 | ARNOLD CRAIG | Director | Stock Award(Grant) at price 0.00 per share. | 2,111 | — |
| 2026-04-27 | HOGAN RANDALL J III | Director | Stock Award(Grant) at price 0.00 per share. | 2,111 | — |
| 2026-04-27 | FONSECA LIDIA PH.D. | Director | Stock Award(Grant) at price 0.00 per share. | 2,111 | — |
| 2026-04-27 | LOFTON KEVIN E | Director | Stock Award(Grant) at price 0.00 per share. | 2,111 | — |
| 2026-02-20 | BLOMQUIST DENISE L | Officer | Stock Gift at price 0.00 per share. | 340 | — |
| 2026-02-19 | KIIL HARRY SKIP | Officer | Conversion of Exercise of derivative security at price 80.00 - 93.08 per share. | 50,876 | $4,624,512 |
| 2026-02-19 | KIIL HARRY SKIP | Officer | Sale at price 97.66 - 97.86 per share. | 52,524 | $5,132,217 |
| 2025-11-20 | BLOMQUIST DENISE L | Officer | Stock Gift at price 0.00 per share. | 170 | — |
| 2025-11-19 | SMITH GREGORY L | Officer | Sale at price 101.93 - 102.08 per share. | 30,000 | $3,058,451 |
WALTER MATTHEW R.
Officer
Sale at price 83.15 per share.
2026-07-08
3,102 sh
$257,931
KIIL HARRY SKIP
Officer
Sale at price 80.44 - 80.45 per share.
2026-06-08
4,189 sh
$336,965
MARINARO MICHAEL
Officer
2026-05-26
18,994 sh
—
WALTER MATTHEW R.
Officer
2026-05-26
9,149 sh
—
BLOMQUIST DENISE L
Officer
2026-05-26
1,712 sh
—
KIIL HARRY SKIP
Officer
2026-05-26
15,195 sh
—
WALL BRETT A
Officer
2026-05-26
26,907 sh
—
MARTHA GEOFFREY S
Chief Executive Officer
2026-05-26
94,963 sh
—
BLOMQUIST DENISE L
Officer
Stock Award(Grant) at price 0.00 per share.
2026-04-27
1,508 sh
—
LEE JOON SUP
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-27
1,803 sh
—
NABEL ELIZABETH G
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-27
2,111 sh
—
GROETELAARS JOHN P
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-27
1,444 sh
—
LEWIS GREGORY P
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-27
2,111 sh
—
JELLISON WILLIAM R
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-27
1,444 sh
—
POWELL KENDALL J
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-27
2,111 sh
—
DONNELLY SCOTT C
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-27
2,111 sh
—
ARNOLD CRAIG
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-27
2,111 sh
—
HOGAN RANDALL J III
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-27
2,111 sh
—
FONSECA LIDIA PH.D.
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-27
2,111 sh
—
LOFTON KEVIN E
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-27
2,111 sh
—
BLOMQUIST DENISE L
Officer
Stock Gift at price 0.00 per share.
2026-02-20
340 sh
—
KIIL HARRY SKIP
Officer
Conversion of Exercise of derivative security at price 80.00 - 93.08 per share.
2026-02-19
50,876 sh
$4,624,512
KIIL HARRY SKIP
Officer
Sale at price 97.66 - 97.86 per share.
2026-02-19
52,524 sh
$5,132,217
BLOMQUIST DENISE L
Officer
Stock Gift at price 0.00 per share.
2025-11-20
170 sh
—
SMITH GREGORY L
Officer
Sale at price 101.93 - 102.08 per share.
2025-11-19
30,000 sh
$3,058,451